Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Zillow Group Inc Class C — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Zillow Group Inc Class C trades at $28.41 (market cap $6.33B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Zillow Group Inc Class C nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Zillow Group Inc Class C for 39 Days on average.
| SYRE | Z | |
|---|---|---|
Market Cap | $7.52B | $6.33B |
Volume | 1,441,031 | 4,060,713 |
Sector | Health | Media |
52-Week High | $108.92 | $78.04 |
52-Week Low | $22.18 | $27.13 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $6.52B | $6.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Zillow Group (Z) trades at $27.97, showing modest daily gains but facing bearish technical signals with the current price near key support levels. The company demonstrates improving fundamentals with revenue growth from $2.2B in 2024 to $2.6B in 2025 and a return to profitability, though valuation metrics remain elevated with a P/E of 121.57. Recent developments include AI integration initiatives and resolution of FTC litigation, while the housing market faces affordability challenges.
The stock presents a mixed outlook with analyst consensus pointing to significant upside potential (average target $52) but near-term headwinds from housing market volatility. Investment opportunity lies in Zillow's platform transition and market leadership, balanced against risks from mortgage rate sensitivity and competitive pressures. The current price near 52-week lows may offer entry points for long-term investors believing in the housing tech transformation story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
